He’s the top expert at characterizing the Standard of Care or What will be the placebo arm. It is difficult for anyone therefore to question the verity of a synthetic placebo arm he might create as “biased” in any ways. That’s my opinion. Having been a skeptic, that is an even better verification. And in that context, whether he ultimately later saw unblinded data or not, the key would be his expertise at the SOC side of the trial.
Makes complete sense as to why Stupp might be consulting.